JCCT Appoints New CEO to Accelerate Growth and Innovation
Dan has over 30 years of experience in the clinical research industry, including key roles in business development and operational leadership. As CEO, he will focus on driving strategic growth, operational excellence, and the continued development of JCCT's site network and therapeutic expertise.
"JCCT has a strong foundation and an exceptional team," said
JCCT conducts clinical trials across a broad spectrum of therapeutic areas, including vaccines, nephrology, and cardiometabolic diseases—backed by deep expertise in first‑in‑human studies, allergy, cardiovascular, endocrine/metabolism, infectious diseases, and more. With the recent addition of a site in
"We've spent the last 20 years building JCCT into a trusted research partner," said
"Dan shares our commitment to science, innovation, and people," added
"JCCT's future is bright," said Board Member
About Johnson County Clin Trials
Founded in 2005, Johnson County Clin Trials is dedicated to advancing modern medicine through scientific disease prevention and clinical excellence. Backed by a growing site network and a steadfast commitment to high-quality research, JCCT delivers dependable data and outstanding care to every study participant.
To learn more, visit www.jcct.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/jcct-appoints-new-ceo-to-accelerate-growth-and-innovation-302479355.html
SOURCE Johnson County Clin Trials
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Club Offers for Travel Enthusiasts in Germany
- Best Software for T-Shirt and Print Design (2026): CorelDRAW Highlighted for Color Separations and Production-Ready Workflows by Software Experts
- Best Crypto Presale to Watch Right Now as BNB and DOGE Stall and Pepeto’s Listing Gap Keeps Widening
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share